The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.
Swertia chirayita, a medicinal herb inhabiting the challenging terrains and high altitudes of the Himalayas, is a rich source of essential phytochemical isolates. Amarogentin, a bitter secoiridoid glycoside from S. chirayita, shows varied activity in several patho-physiological conditions, predomina...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090637&type=printable |
| _version_ | 1826799124524040192 |
|---|---|
| author | Shantanu Shukla Khushboo Bafna Durai Sundar Sunil S Thorat |
| author_facet | Shantanu Shukla Khushboo Bafna Durai Sundar Sunil S Thorat |
| author_sort | Shantanu Shukla |
| collection | DOAJ |
| description | Swertia chirayita, a medicinal herb inhabiting the challenging terrains and high altitudes of the Himalayas, is a rich source of essential phytochemical isolates. Amarogentin, a bitter secoiridoid glycoside from S. chirayita, shows varied activity in several patho-physiological conditions, predominantly in leishmaniasis and carcinogenesis. Experimental analysis has revealed that amarogentin downregulates the cyclooxygenase-2 (COX-2) activity and helps to curtail skin carcinogenesis in mouse models; however, there exists no account on selective inhibition of the inducible cyclooxygenase (COX) isoform by amarogentin. Hence the computer-aided drug discovery methods were used to unravel the COX-2 inhibitory mechanism of amarogentin and to check its selectivity for the inducible isoform over the constitutive one. The generated theoretical models of both isoforms were subjected to molecular docking analysis with amarogentin and twenty-one other Food and Drug Authority (FDA) approved lead molecules. The post-docking binding energy profile of amarogentin was comparable to the binding energy profiles of the FDA approved selective COX-2 inhibitors. Subsequent molecular dynamics simulation analysis delineated the difference in the stability of both complexes, with amarogentin-COX-2 complex being more stable after 40ns simulation. The total binding free energy calculated by MMGBSA for the amarogentin-COX-2 complex was -52.35 KCal/mol against a binding free energy of -8.57 KCal/mol for amarogentin-COX-1 complex, suggesting a possible selective inhibition of the COX-2 protein by the natural inhibitor. Amarogentin achieves this potential selectivity by small, yet significant, structural differences inherent to the binding cavities of the two isoforms. Hypothetically, it might block the entry of the natural substrates in the hydrophobic binding channel of the COX-2, inhibiting the cyclooxygenation step. To sum up briefly, this work highlights the mechanism of the possible selective COX-2 inhibition by amarogentin and endorses the possibility of obtaining efficient, futuristic and targeted therapeutic agents for relieving inflammation and malignancy from this phytochemical source. |
| first_indexed | 2024-12-17T12:51:03Z |
| format | Article |
| id | doaj.art-1ab697c6e9604dfbbc353e33781e01c0 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2025-03-17T00:30:06Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1ab697c6e9604dfbbc353e33781e01c02025-02-21T05:35:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e9063710.1371/journal.pone.0090637The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.Shantanu ShuklaKhushboo BafnaDurai SundarSunil S ThoratSwertia chirayita, a medicinal herb inhabiting the challenging terrains and high altitudes of the Himalayas, is a rich source of essential phytochemical isolates. Amarogentin, a bitter secoiridoid glycoside from S. chirayita, shows varied activity in several patho-physiological conditions, predominantly in leishmaniasis and carcinogenesis. Experimental analysis has revealed that amarogentin downregulates the cyclooxygenase-2 (COX-2) activity and helps to curtail skin carcinogenesis in mouse models; however, there exists no account on selective inhibition of the inducible cyclooxygenase (COX) isoform by amarogentin. Hence the computer-aided drug discovery methods were used to unravel the COX-2 inhibitory mechanism of amarogentin and to check its selectivity for the inducible isoform over the constitutive one. The generated theoretical models of both isoforms were subjected to molecular docking analysis with amarogentin and twenty-one other Food and Drug Authority (FDA) approved lead molecules. The post-docking binding energy profile of amarogentin was comparable to the binding energy profiles of the FDA approved selective COX-2 inhibitors. Subsequent molecular dynamics simulation analysis delineated the difference in the stability of both complexes, with amarogentin-COX-2 complex being more stable after 40ns simulation. The total binding free energy calculated by MMGBSA for the amarogentin-COX-2 complex was -52.35 KCal/mol against a binding free energy of -8.57 KCal/mol for amarogentin-COX-1 complex, suggesting a possible selective inhibition of the COX-2 protein by the natural inhibitor. Amarogentin achieves this potential selectivity by small, yet significant, structural differences inherent to the binding cavities of the two isoforms. Hypothetically, it might block the entry of the natural substrates in the hydrophobic binding channel of the COX-2, inhibiting the cyclooxygenation step. To sum up briefly, this work highlights the mechanism of the possible selective COX-2 inhibition by amarogentin and endorses the possibility of obtaining efficient, futuristic and targeted therapeutic agents for relieving inflammation and malignancy from this phytochemical source.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090637&type=printable |
| spellingShingle | Shantanu Shukla Khushboo Bafna Durai Sundar Sunil S Thorat The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita. PLoS ONE |
| title | The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita. |
| title_full | The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita. |
| title_fullStr | The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita. |
| title_full_unstemmed | The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita. |
| title_short | The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita. |
| title_sort | bitter barricading of prostaglandin biosynthesis pathway understanding the molecular mechanism of selective cyclooxygenase 2 inhibition by amarogentin a secoiridoid glycoside from swertia chirayita |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090637&type=printable |
| work_keys_str_mv | AT shantanushukla thebitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita AT khushboobafna thebitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita AT duraisundar thebitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita AT sunilsthorat thebitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita AT shantanushukla bitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita AT khushboobafna bitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita AT duraisundar bitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita AT sunilsthorat bitterbarricadingofprostaglandinbiosynthesispathwayunderstandingthemolecularmechanismofselectivecyclooxygenase2inhibitionbyamarogentinasecoiridoidglycosidefromswertiachirayita |